In order to demonstrate the reduction of target cell lysis by blocking of the anti-CD3 Fab, the dose-dependent T-cell killing of FOLR1-positive tumor cells by Prot-FOLR1-TCBs was measured after 48 h. The gene discussed is FOLR1; the disease is neoplasm.